Is Ideaya Biosciences Inc (IDYA) Stock About to Get Hot Wednesday?

Overall market sentiment has been neutral on Ideaya Biosciences Inc (IDYA) stock lately. IDYA receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Ideaya Biosciences Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on IDYA!

See Full IDYA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With IDYA Stock Today?

Ideaya Biosciences Inc (IDYA) stock is trading at $30.77 as of 11:16 AM on Wednesday, Nov 22, a gain of $0.27, or 0.89% from the previous closing price of $30.50. The stock has traded between $30.04 and $31.50 so far today. Volume today is below average. So far 59,107 shares have traded compared to average volume of 999,440 shares.

More About Ideaya Biosciences Inc

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Click Here to get the full Stock Report for Ideaya Biosciences Inc stock.